Founders
Founding Partner
Founding Partner
United States
Account Managers
Account Manager
Account Manager
Jeremy brings 15 years of experience in healthcare, both as a sell-side analyst and as an investor relations advisor. Jeremy covered both medical devices and healthcare services as an analyst at such firms as Bank of America, Oppenheimer, and Cantor Fitzgerald, and he was quoted regularly in the financial press. As the founder of Whalebone Advisory, he built extensive experience developing and executing investor relations strategies for pre-IPO and publicly-traded healthcare companies and counseling senior executives on messaging to Wall Street, including guidance philosophy, earnings preparation, and corporate access plans. Jeremy presently serves on the boards of the Edgemont Community Council and of the Fraternal Order of Bendin-Sosnowicer. Jeremy earned an MBA in Finance from the Leonard N. Stern School of Business at New York University, a Diploma in Economics from the London School of Economics, and a BA in Economics and Political Science from the University of Chicago.
Dan Ferry joins LifeSci Advisors from Guggenheim Securities, where he specialized in connecting healthcare companies with buy-side investors, venture capitalists, KOLs, sell-side analysts, and the investment bank. Mr. Ferry spent nearly 4 years at Guggenheim Securities putting together numerous non-deal roadshows, collecting feedback from investors, and helping shape investor outreach strategies. Prior to Guggenheim, Mr. Ferry worked at Lazard Capital Markets where he participated in many successful healthcare company financings. Over the course of his career, Mr. Ferry has developed long-standing relationships with the healthcare investment community. Mr. Ferry received a BS in Finance from the University of Southern California. He currently resides with his wife and three children in the Boston area.
Ashley R. Robinson has 20 years of experience in institutional equities, with a focus on the healthcare sector. He began his Wall Street career at Lehman Brothers Holdings, Inc., where he spent time in both the New York and Boston offices. Following this, Mr. Robinson spent 14 years at Leerink Swann (now Leerink Partners, LLC), where he was a Managing Director and Partner. At Leerink, Mr. Robinson helped establish and build the institutional franchise, and was responsible for covering the firm’s largest accounts, which allowed him to develop deep relationships with many leading healthcare investors. During his tenure, Mr. Robinson served as “Deal Captain” on most of Leerink’s capital markets transactions, and was the primary liaison between sales and equity capital markets.
Prior to joining LifeSci, Mr. Robinson was the Healthcare Product Specialist and Sector Head at Guggenheim Securities, LLC, where he was responsible for building a research franchise in that sector. Mr. Robinson earned a Bachelor of Arts degree from Hobart College. He double-majored in Economics and Russian Area Studies, and played Soccer, Lacrosse, and Squash.
Tim McCarthy brings over 18 years of investment experience across all healthcare sectors and capitalization ranges, focusing on life science investments at Kingdon Capital Management, Millennium Partners, Healthco/SAC Capital and Sabby Management. His extensive buy-side track record, when combined with specialty pharmaceutical sell-side research at CSFB and Lehman Brothers, and public accounting experience at Arthur Andersen LLP, provides a well-rounded perspective to the team.
Tim earned a BS with Special Attainments in Commerce from Washington and Lee University and an MBA in Finance and International Business from the Leonard N. Stern School of Business at New York University. He is a CFA charter holder and completed all CPA qualifications.
Managing Director, Relationship Manager
Corey Davis, Ph.D. | Relationship Manager
Corey Davis has 22 years of experience as a sell-side equity research analyst covering a diverse array of biotech and specialty pharmaceutical companies. He joins most recently from Seaport Global Securities, and has previously been Managing Directors at Canaccord Genuity, Jefferies, HC Wainwright, Natixis Bleichroeder, and J.P. Morgan (and its predecessor Hambrecht & Quist). His therapeutic expertise spans the gamut from ophthalmology, dermatology, gastroenterology, endocrinology, urology, and oncology to anti-infectives, pulmonary, cardiovascular, pain, and all of the CNS disorders (depression, anxiety, schizophrenia, ADHD, multiple sclerosis, Parkinson’s, epilepsy, insomnia, narcolepsy, migraine, etc.). He has also worked with many different Orphan Disease-related companies. He has formally covered well over 200 names throughout the course of his career with a special focus on small and mid-cap companies. He is particularly adept at advising on topics such as earnings models and projections, guidance philosophies, valuation approaches, clinical trial design, optimizing data disclosure events, non-deal roadshows, and hosting R&D days. He has won numerous awards including multiple Institutional Investor rankings, and The Wall Street Journal’s “Best on the Street”. He graduated magna cum laude from Middlebury College in 1991 and received his Ph.D. in molecular biology from Princeton University in 1997.
Bruce Mackle brings over 20 years of healthcare-dedicated experience in the financial industry on the sell-side, on the buy-side and as an investor relations advisor. Over the course of his career, Bruce primarily served as a healthcare trading desk analyst and a healthcare sector sales specialist at firms including Wells Fargo, UBS, HSBC, and most recently, JMP. Prior to JMP, he worked at Bertner Advisors, a healthcare-focused investor relations advisory firm, where he managed a client portfolio of both public and pre-IPO companies. His buy-side experience includes positions at two healthcare-dedicated funds, Tokum Capital and Steeple Capital. Bruce began his Wall Street career as a healthcare equity research analyst at Gruntal & Co. and UBS. He earned an M.B.A. in Finance and Economics from New York University’s Stern School of Business and a B.A. in History from Cornell University.
Non-Deal Roadshows
Casey DeBaecke has more than 25 years of experience in Institutional Equity Sales. She began her career in the Boston Office of First Boston Corporation working in Equity Research. Casey then spent fifteen years at Credit Suisse where she was responsible for Institutional Equity Research Sales in the MidAtlantic Region. Prior to joining LifeSci Advisors, Casey worked for 10 years at UBS in the Institutional Equities Group providing Research Sales coverage to accounts in the MidAtlantic territory. Casey graduated from Boston College with a Bachelor of Science in Finance and a Minor in Asian Studies.
Kevin O’Gorman has 20 years of experience as an institutional equity salesperson. Kevin began his career in the New York office of PaineWebber & Co. and spent more than half his career with Buckingham Research, where he was a partner. He brings an extensive network of institutional relationships from the Midwest, greater New York and United Kingdom markets. He joins LifeSci Advisors from Oppenheimer & Co and has an MBA from Fordham Universality and an undergraduate degree in English Literature from the Catholic University of America.
Chuck Padala has spent over 25 years in Institutional Equity Sales & Trading. He began his career at SunTrust/Robinson Humphrey, where he spent 20 years, and supervised the firm’s NY Sales & Trading desks. Chuck later joined Brean Capital where he ran the firm’s Equities division and was Head of ECM, followed by two years at Longbow Research as Head of Institutional Sales. Prior to joining LifeSci Advisors, Chuck served as President of the Securities Traders Association’s NY affiliate and served two consecutive terms on STA’s national Board of Governors. STA is the largest organization representing professional traders and was founded as a grass roots response to the founding of the SEC in 1934, in order to give market participants a voice in Washington DC. Chuck graduated with honors from New York University with a Bachelor of Arts in Humanities.
Non-Deal Roadshows – Private Wealth
Eric Ribner joined LifeSci Advisors as a Vice President in October 2017, focusing on the firm’s Retail Non-Deal Roadshow (NDR) efforts. Previously, he was a Senior Loan Advisor at Multifunding LLC where he advised businesses on their loan and debt options. Previously, he served as Chief Financial Officer of MetalX. Eric spent more than 20 years working on Wall Street in various capacities, including as an Executive Director of Institutional Sales at Oppenheimer & Co. for 9 years and on the buy-side, first as a Managing Director of Equity Research at NorthStar Capital Funds and then as a Senior Vice President at George Weiss Associates, where he helped manage over $200 million in equities in the financial, industrial, energy and metal sectors. Eric resides in New York and has two children
Corporate Communications
Monique brings to LifeSci nearly 20 years of Wall Street experience. Her expertise includes roles as both a senior institutional investment analyst with large global asset managers, and as a trusted investor relations advisor providing insight and strategic counsel to senior management teams.
Before joining LifeSci, Monique was a founding partner at Access Capital Advisors, where she partnered with senior management teams to develop investor communications programs tailored
to best convey each client’s value proposition to Wall Street. She and her partner thoughtfully crafted messaging, developed positioning, and targeted key investors.
Prior to her career in investor relations, Monique spent 15 years investing in small-cap healthcare companies as a fundamental research analyst. Her experience encompasses both large
multi-national firms like Deutsche Asset Management and Fidcuciary Trust and small boutique firms like Rochdale Investment Management and Palisade Capital Management. At each firm, Monique provided in-depth fundamental research and analysis to support her
investment recommendations. She was an active member on each firm’s investment committee responsible for firm-wide sector allocation decisions.
Monique began her career at a Washington D.C. industry trade association serving as a liaison between government and industry interpreting government regulations and advising on the
rulemaking process. Her understanding of chemistry and business provided the background to translate highly technical and scientific manufacturing processes for Washington regulators at FDA, EPA, and OSHA.
Monique has her MBA in Finance from New York University Stern School of Business, and dual degrees in Chemistry and German from St. Olaf College. She also holds her Series 7 and Series
66 licenses.
She is an avid triathlete having completed seven Ironman races. When not training, she is diligently in search of the perfect food pairing for the beloved Burgundy wines in her collection.
She and her husband live in Manhattan with their 140 pound English Mastiff, Bella.
Garth Russell has more than 15 years of healthcare IR and corporate communications experience. He has successfully worked with biotechnology and life science companies to establish investor relations capabilities that dovetail with broader corporate communications programs, including public relations and social media. Garth has provided strategic IR counsel to companies through IPOs, secondary offerings, M&A transactions and changes in management. Garth previously worked with KCSA Strategic Communications as Managing Director of Investor Relations, during which his responsibilities included overseeing the firm’s healthcare practice. He holds a B.S. in Marketing from SUNY Plattsburgh. Garth is a NIRI-National and NIRI-New York chapter member.
Glenn Garmont brings to LifeSci nearly two decades of experience, not only in financial communications, but also as a sell-side equity research analyst. Prior to LifeSci, Glenn served as Senior Vice President at Rx Communications LLC, and, before that, Argot Partners, where he developed and executed strategic IR programs for an array of public and private companies across all development stages, in the biotechnology, specialty pharmaceuticals and medical device sectors. He also served as a Vice President on the health care team at ICR.
Before transitioning to investor relations, Glenn spent 12 years as a sell-side equity research analyst, first as a senior associate on multiple highly ranked research teams at Salomon Smith Barney, and then as a senior publishing analyst at boutique banking firms First Albany and ThinkEquity. As a senior analyst, Glenn built his expertise with research focused on health care services, including health care information technology, pharmacy benefit managers, pharmaceutical contract research and sales organizations, disease management, pharmacy automation, drug distribution and managed care.
Glenn earned a B.S. in Finance from Rutgers University and an MBA in Finance from the Stern School of Business at New York University.
Allison Blum is the Director of Scientific Communications at LifeSci Advisors. Allison has extensive communications, scientific writing and academic research experience in diverse areas including medicinal chemistry, neuroscience, stem cell biology, precision medicine and genomics.
Prior to joining LifeSci, Allison was the Director of Scientific and Research Strategy at the Institute for Genomic Medicine at Columbia University Medical Center. In this role she oversaw a complex grant and research portfolio with industry, clinical, government and foundation sponsors while also directing the Institute’s communications and grant writing. Prior to Columbia, Allison spent eight years with the Howard Hughes Medical Institute, the largest philanthropic organization supporting biomedical research in the United States, first as a researcher and then overseeing science operations for Howard Hughes Investigators at Columbia, NYU, Princeton, the University of Pennsylvania, Albert Einstein College of Medicine and the Aaron Diamond AIDS Research Center.
Allison earned her Ph.D. in Biological Sciences from the Watson School of Biological Sciences at Cold Spring Harbor Laboratory and holds a Master of Science in Organic Chemistry and Bachelor of Science in Biochemistry from American University.
Christopher Chu brings over 20 years of experience providing comprehensive investor relations programming and corporate communications across broad sectors, including healthcare and biotechnology. He has led strategic, internal and crisis communications, and transaction advisory services for IPOs, M&A, and public financings. Examples of his diverse transaction work include the reverse merger and introduction of Cellular Biomedicine Group to the capital markets, the IPO of Markit, its investor relations program buildout and subsequent merger with IHS; and also, the Republic of Ghana’s $1B sovereign bond raise. Before joining LifeSci, he held senior agency roles with The Piacente Group, Grayling, and Taylor-Rafferty. Additionally, he has led client investor relations advisory services on behalf of the Depositary Receipts group at J.P. Morgan. He completed pre-med studies and earned a B.A. in English from Stony Brook University. He also holds a M.S. in Information Systems from Pace University.
Finance
KOL Events
Vice President, KOL Strategy and Management
Investor Targeting
Managing Director
Business Development
Europe
Account Managers
Managing Director, Head of Europe
Account Manager
Hans is an investor relations and corporate communications executive with over 25 years of corporate and agency experience. He has been involved in shaping the communication strategies for private financings, M&A, partnering, and IPOs, which in aggregate exceed $1.5 billion. Recently he was Head of Investor Relations & Corporate Communications of Symetis, which was acquired by Boston Scientific for EUR 425 million. He held the same position at Amsterdam Molecular Therapeutics/uniQure at the time of the company’s first IPO in 2007, and from 2000 until 2007 at IsoTis OrthoBiologics, managing the Company’s IPO, M&A transactions, and its three stock market listings in Amsterdam, Zurich, and Toronto. At the start of his career, Hans worked with Amgen International for five years, as it was establishing its footprint outside the U.S. Hans has BA degrees in Portuguese Linguistics & Literature, the Philosophy of Law, and Translation Sciences, and an MA in Italian Literature & Linguistics from the University of Amsterdam. He is fluent in Dutch, English, Italian, and French. A Dutch national, Hans is based in Switzerland, and is an avid open water swimmer.
Associate Relationship Manager
Ligia is experienced in global healthcare and financial communication. Working at Edelman and Prosek Partners, she built global brand awareness and shaped the communication strategies around M&A, corporate restructurings, FDA and EMA approvals for clients. Ligia is based in London, UK.
Directrice Media France
An experienced public relations professional in France, having previously worked at Edelman’s Paris office. Sophie runs financial communication and retail media relations in French speaking territories. Sophie is based in Paris, France.
Non-Deal Roadshows
Managing Director & Head of European Corporate Access
Niki started in institutional equity sales almost 20 years’ ago, initially in US equity sales at Cowen and JP Morgan, and then specialised in US healthcare stocks & later also European Healthcare stocks at JP Morgan and Fortis Bank, with a particular focus on Biotechnology companies at the latter. In 2009 she founded Aetia Ltd, a UK based healthcare specialist financial services firm offering capital raising and investor access services to private and public healthcare companies around the world, further developing her long-standing relationships with the healthcare investment community across Europe. During her career, Niki has managed numerous deal and non-deal roadshows across the UK and Europe and has a successful track record raising capital for a wide range of both public and private global life science companies at various stages of development. Prior to her investment banking career, Niki worked at Pricewaterhouse Coopers. She has a BSc in Business Management and Languages from Kings’ College, London.
Managing Director, Switzerland
Floriane, is managing director of Investment Connections (Geneva, Switzerland), which she founded in 2004. Her firm has developed close working relationships with a broad spectrum of European investors, including generalists, family offices, high net worth individuals and institutional investors including healthcare specialists. Previously, Floriane worked with European Investor Relations SA (now Voxia), where she was responsible for the internal management of the EIR team as well as assisting clients directly with their European roadshows. Floriane holds a Master Degree in Business Management from HEC (Hautes Etudes Commerciales) – University of Geneva.
Managing Director, France & Germany
Anne has over 20 years’ experience in institutional equity sales. She started her career at Banque Harwanne and joined the Banque NSM (ABN AMRO Group) where she became head of Institutional Sales Europe. In 2004, she founded Finapsis an independent advisory firm specialising in fundraisings for listed and non listed companies, where she completed numerous transactions in healthcare and software. Anne graduated from the Reims Management School.
Managing Director
Norma has over 20 years’ experience in institutional equity sales and has been heavily involved in marketing PIPEs, IPOs and secondary offerings to European specialist healthcare & tech funds. For the last 8 years Norma was healthcare specialist sales on the US institutional equity desk at Oppenheimer in London, covering UK, Swiss and German specialist investors. She spent the first half of her career on the US equity sales desk at CIBC in London where she had overall responsibility for Swiss investors and managed a team selling the firm’s US equity research product into Switzerland while personally focusing on healthcare and technology stocks. Norma earned a BSc in Financial Economics from University of London.
Israel
Account Managers
Managing Director, Israel
Non-Deal Roadshows – Institutional and Private Wealth
